Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-li...
Redeye comment on Flexions Q2 report. Excluding FX effects, operations grew by 4–5% during the quart...
Redeye is not surprised by the announced directed share issue of SEK6m.
Idag, fredag 29 augusti, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv2 2025...
Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-lin...
Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase ...
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det andra ...
Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encou...
Redeye updates on GiG Software after Q2-results which were in line with expectations.
The offering represents a 55% discount from yesterday's trading, and we find that Hargreaves has no ...
Redeye comments on Lytix Biopharma’s Q2 report 2025 in an extended update.
Redeye comments on FluoGuide’s Q2 2025 report. The company’s recent progress update mostly aligned w...
Redeye comments on the now confirmed partnering with industry giant Quest Diagnostics for channel co...
Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments fo...
Redeye comments on Jumpgate’s Q2 report, which was broadly in line with our estimates, with the exce...
Redeye comments on Nekkar’s Q2 report, that presented mixed Q2 figures during a relatively slow peri...
Redeye comments on Fable Media Group’s Q2 results, aligning with the preliminary figures and our est...
Train Alliance levererade ett starkt andra kvartal med stigande intäkter och en förbättrad rörelsema...
